| 000 | 01379 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250514021518.0 | ||
| 264 | 0 | _c20020214 | |
| 008 | 200202s 0 0 eng d | ||
| 022 | _a1354-3784 | ||
| 024 | 7 |
_a10.1517/13543784.10.6.1099 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMitsiades, C S | |
| 245 | 0 | 0 |
_aMolecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. _h[electronic resource] |
| 260 |
_bExpert opinion on investigational drugs _cJun 2001 |
||
| 300 |
_a1099-115 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAndrogen Antagonists _xpharmacology |
| 650 | 0 | 4 | _aAndrogen Receptor Antagonists |
| 650 | 0 | 4 |
_aAndrogens _xmetabolism |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInsulin-Like Growth Factor I _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aReceptor, IGF Type 1 _xmetabolism |
| 650 | 0 | 4 |
_aReceptors, Androgen _xmetabolism |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 700 | 1 | _aKoutsilieris, M | |
| 773 | 0 |
_tExpert opinion on investigational drugs _gvol. 10 _gno. 6 _gp. 1099-115 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/13543784.10.6.1099 _zAvailable from publisher's website |
| 999 |
_c11684292 _d11684292 |
||